Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Salivary Gland Neoplasms × eribulin × 1 year × Clear all

Sponsor

Conditions

Breast Neoplasms 24 Triple Negative Breast Neoplasms 10 Sarcoma 5 Neoplasm Metastasis 5 Liposarcoma 3 Inflammatory Breast Neoplasms 3 Urinary Bladder Neoplasms 2 Leiomyosarcoma 2 Carcinoma, Transitional Cell 2 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Refractory Solid Tumors 1 Recurrence 1 Ketosis 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1 HR+HER2- Breast Cancer 1 HER2-negative Metastatic Breast Cancer 1 HER2-low Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Colorectal Neoplasms 1 Brest Cancer 1 Brain Neoplasms 1 Advanced Breast Cancer 1

Interventions

pembrolizumab 6 Magnetic Resonance Spectroscopy 6 Specimen Handling 5 Carboplatin 5 Docetaxel 4 Biopsy 4 trastuzumab deruxtecan 3 darolutamide 3 Trastuzumab 3 Platinum 3 Goserelin 3 Cisplatin 3 sacituzumab govitecan 2 pertuzumab 2 entrectinib 2 Leuprolide 2 Ado-Trastuzumab Emtansine 2 1,2-diaminocyclohexaneplatinum II citrate 2 zanidatamab 1 trastuzumab biosimilar HLX02 1 spartalizumab 1 selinexor 1 pyrotinib 1 luprolide acetate gel depot 1 lenvatinib 1 larotrectinib 1 enfortumab vedotin 1 dehydroftorafur 1 ceralasertib 1 camrelizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡